PGD for hereditary breast and ovarian cancer: the route to universal tests for BRCA1 and BRCA2 mutation carriers

Drüsedau, Marion; Dreesen, Jos C; Derks-Smeets, Inge; Coonen, Edith; van Golde, Ron; van Echten-Arends, Jannie; Kastrop, Peter M M; Blok, Marinus J; Gómez-García, Encarna; Geraedts, Joep P; Smeets, Hubert J; de Die-Smulders, Christine E; Paulussen, Aimée D
December 2013
European Journal of Human Genetics;Dec2013, Vol. 21 Issue 12, p1361
Academic Journal
Preimplantation Genetic Diagnosis (PGD) is a method of testing in vitro embryos as an alternative to prenatal diagnosis with possible termination of pregnancy in case of an affected child. Recently, PGD for hereditary breast and ovarian cancer caused by BRCA1 and BRCA2 mutations has found its way in specialized labs. We describe the route to universal single-cell PGD tests for carriers of BRCA1/2 mutations. Originally, mutation-specific protocols with one or two markers were set up and changed when new couples were not informative. This route of changing protocols was finalized after 2 years with universal tests for both BRCA1 and BRCA2 mutation carriers based on haplotyping of, respectively, 6 (BRCA1) and 8 (BRCA2) microsatellite markers in a multiplex PCR. Using all protocols, 30 couples had a total of 47 PGD cycles performed. Eight cycles were cancelled upon IVF treatment due to hypostimulation. Of the remaining 39 cycles, a total of 261 embryos were biopsied and a genetic diagnosis was obtained in 244 (93%). In 34 of the 39 cycles (84.6%), an embryo transfer was possible and resulted in 8 pregnancies leading to a fetal heart beat per oocyte retrieval of 20.5% and a fetal heart beat per embryonic transfer of 23.5%. The preparation time and costs for set-up and validation of tests are minimized. The informativity of microsatellite markers used in the universal PGD-PCR tests is based on CEPH and deCODE pedigrees, making the tests applicable in 90% of couples coming from these populations.


Related Articles

  • Population-Based Study of BRCA1 and BRCA2 Mutations in 1035 Unselected Finnish Breast Cancer... Syrjakoski, Kirsi; Vahteristo, Pia // JNCI: Journal of the National Cancer Institute;09/20/2000, Vol. 92 Issue 18, p1529 

    Discusses a study of mutations of genes involved in hereditary breast and/or ovarian cancer of Finnish patients. Occurrence of mutations; Collection of blood samples from patients; Distribution of questionnaires for the patients; Differences in dichotomous variables; Frequency of mutations in...

  • Biology of hereditary breast and ovarian cancers. Tommasi, S. // Annals of Oncology;Nov2013 Supplement 8, Vol. 24 Issue suppl_8, pviii7 

    No abstract available.

  • Haplotype analysis of BRCA1 gene reveals a new gene rearrangement: characterization of a 19.9 KBP deletion. Tancredi, Mariella; Sensi, Elisa; Cipollini, Giovanna; Aretini, Paolo; Lombardi, Grazia; Di Cristofano, Claudio; Presciuttini, Silvano; Bevilacqua, Generoso; Caligo, Maria Adelaide // European Journal of Human Genetics;Sep2004, Vol. 12 Issue 9, p775 

    Germ-line mutations in the BRCA1 gene cause hereditary predisposition to breast and ovarian cancer. BRCA1 and BRCA2 mutations account for about 40% of high-risk families. Mutation-screening methods generally focus on genomic DNA and are usually PCR based; they enable the detection of sequence...

  • Copy Number Variation Analysis in Familial BRCA1/2-Negative Finnish Breast and Ovarian Cancer. Kuusisto, Kirsi M.; Akinrinade, Oyediran; Vihinen, Mauno; Kankuri-Tammilehto, Minna; Laasanen, Satu-Leena; Schleutker, Johanna // PLoS ONE;Aug2013, Vol. 8 Issue 8, p1 

    Background: Inherited factors predisposing individuals to breast and ovarian cancer are largely unidentified in a majority of families with hereditary breast and ovarian cancer (HBOC). We aimed to identify germline copy number variations (CNVs) contributing to HBOC susceptibility in the Finnish...

  • Large Genomic Rearrangements of BRCA1 and BRCA2 among Patients Referred for Genetic Analysis in Galicia (NW Spain): Delimitation and Mechanism of Three Novel BRCA1 Rearrangements. Fachal, Laura; Blanco, Ana; Santamariña, Marta; Carracedo, Angel; Vega, Ana // PLoS ONE;Mar2014, Vol. 9 Issue 3, p1 

    In the Iberian Peninsula, which includes mainly Spain and Portugal, large genomic rearrangements (LGRs) of BRCA1 and BRCA2 have respectively been found in up to 2.33% and 8.4% of families with hereditary breast and/or ovarian cancer (HBOC) that lack point mutations and small indels. In Galicia...

  • Non-random transmission of mutant alleles to female offspring of BRCA1 carriers in Poland. Gronwald, J.; Gorski, B.; Byrski, T.; Huzarski, T.; Jakubowska, A.; Menkiszak, J.; Narod, S.A.; Lubinski, J. // Journal of Medical Genetics;Sep2003, Vol. 40 Issue 9, p719 

    Examines the prevalence of founder BRCA1 mutations among unaffected daughters of 91 carrier women in Poland. Founder mutations in BRCA1; Segregation of mutant and non-mutant alleles; Implications both for genetic counseling and for the calculation of penetrance estimates using pedigree-based...

  • BRCA mutations in Italian breast/ovarian cancer families.  // European Journal of Human Genetics;Feb2002, Vol. 10 Issue 2, p150 

    Studies the BRCA gene mutation in breast/ovarian cancer families in Italy. Types of BRCA gene mutations; Ethnic populations associated with the mutation; Characteristics of the BRCA families of Italian ancestry.

  • Genetic risk in context: calculating the penetrance of BRCA1 and BRCA2 mutations. Burke, Wylie; Austin, Melissa A. // JNCI: Journal of the National Cancer Institute;8/21/2002, Vol. 94 Issue 16, p1185 

    Editorial. Estimates the penetrance of BRCA1 and BRCA2 gene mutations. Chance of developing breast or ovarian cancer in the presence of a deleterious mutation; Consequences of preventive interventions.

  • Association of the I1307K APC mutation with hereditary and sporadic breast/ovarian cancer: more questions than answers. Gershoni-Baruch, R; Patael, Y; Dagan; Figer, A; Kasinetz, L; Kadouri, E; Sade, R Bruchim Bar; Friedman, E // British Journal of Cancer;7/15/2000, Vol. 83 Issue 2, p153 

    The frequency of the APC I1307K mutation and its association with disease pattern was examined in 996 Ashkenazi women consisting of individuals with either sporadic (n = 382) or hereditary (n = 143) breast and/or ovarian cancer; asymptomatic BRCA1/2 mutation carriers (185delAG, 5382insC and...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics